Home › Funds › CLIFFORD SWAN INVESTMENT COUNSEL LLC › ABT

CLIFFORD SWAN INVESTMENT COUNSEL LLC position in ABT

ABBOTT LABORATORIES · Health Care

CLIFFORD SWAN INVESTMENT COUNSEL LLC reported holding 198,883 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$19.7M, representing 0.71% of its reported portfolio and ranking #46 among its reported holdings. CLIFFORD SWAN INVESTMENT COUNSEL LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)198.88K sh
Reported value held$19.66M
Portfolio Weight0.71%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How CLIFFORD SWAN INVESTMENT COUNSEL LLC's ABT position evolved

CLIFFORD SWAN INVESTMENT COUNSEL LLC first disclosed a stake in ABT in Q3 2023 at 232,450 shares (US$22.5M). The position peaked in Q2 2025 at 209,323 shares, worth US$28.5M. Across 13 filings, CLIFFORD SWAN INVESTMENT COUNSEL LLC increased the stake 0 time(s), trimmed it 10 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 198,883 shares valued at US$19.7M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 232.45K $22.51M New
Q4 2023 231.65K $25.50M Hold
Q1 2024 223.19K $25.37M Reduce
Q2 2024 221.52K $23.02M Reduce
Q3 2024 217.77K $24.83M Reduce
Q4 2024 213.70K $24.17M Reduce
Q1 2025 212.08K $28.13M Reduce
Q2 2025 209.32K $28.47M Reduce
Q3 2025 208.16K $27.88M Reduce
Q4 2025 204.62K $25.64M Reduce
Q1 2026 201.30K $20.67M Reduce
Q2 2026 199.71K $18.12M Reduce
Q3 2026 198.88K $19.66M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has CLIFFORD SWAN INVESTMENT COUNSEL LLC held ABT?

CLIFFORD SWAN INVESTMENT COUNSEL LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is CLIFFORD SWAN INVESTMENT COUNSEL LLC's current position in ABT?

As of Q3 2026, CLIFFORD SWAN INVESTMENT COUNSEL LLC holds 198.88K shares of ABT (ABBOTT LABORATORIES), valued at $19.66M, representing 0.71% of its reported portfolio and ranking #46.

Has CLIFFORD SWAN INVESTMENT COUNSEL LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), CLIFFORD SWAN INVESTMENT COUNSEL LLC held unchanged its position in ABT. The position peaked in Q2 2025 at 209.32K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.